Vitronectin-αvβ3 integrin engagement directs hypoxia-resistant mTOR activity and sustained protein synthesis linked to invasion by breast cancer cells

Cancer Research

Volumn 73, Issue 14, 2013, Pages 4571-4578

  Pola, Carolina ^a   Formenti, Silvia C ^a,b   Schneider, Robert J ^a,b  

^a Department of Microbiology ^*  (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; VITRONECTIN; VITRONECTIN RECEPTOR;

ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL; CELL HYPOXIA; CELL INVASION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RNA TRANSLATION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BREAST NEOPLASMS; CELL ADHESION; CELL HYPOXIA; CELL LINE, TUMOR; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; FOCAL ADHESION KINASE 1; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; INTEGRIN ALPHAVBETA3; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; PROTEIN BIOSYNTHESIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES; VITRONECTIN;

EID: 84880859236     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0218     Document Type: Article

References (33)

1. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-79.
2. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1:46-54.
3. Nelson CM, Bissell MJ. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2006;22:287-309.
4. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-49.
5. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008;8:180-92.
6. Connolly E, Braunstein S, Formenti S, Schneider RJ. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol Cell Biol 2006;26:3955-65.
7. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999;68:913-63.
8. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer 2010;10:254-66.
9. Holcik M, Sonenberg N. Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 2005;6:318-27.
10. Gorrini C, Loreni F, Gandin V, Sala LA, Sonenberg N, Marchisio PC, et al. Fibronectin controls cap-dependent translation through beta1 integrin and eukaryotic initiation factors 4 and 2 coordinated pathways. Proc Natl Acad Sci USA 2005;102:9200-05.
11. Han S, Khuri FR, Roman J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 2006;66:315-23.
12. Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002;295:140-43.
13. Cabodi S, del Pilar Camacho-Leal M, Di Stefano P, Defilippi P. Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer 2010;10:858-70.
14. Takayama S, Ishii S, Ikeda T, Masamura S, Doi M, Kitajima M. The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression. Anticancer Res 2005;25:79-83.
15. Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, et al. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 2007;67:5821-30.
16. Aaboe M, Offersen BV, Christensen A, Andreasen PA. Vitronectin in human breast carcinomas. Biochim Biophys Acta 2003;1638:72-82.
17. Meyer T, Marshall JF, Hart IR. Expression of alphav integrins and vitronectin receptor identity in breast cancer cells. Br J Cancer 1998; 77:530-36.
18. Gandin V, Brina D, Marchisio PC, Biffo S. JNK inhibition arrests cotranslational degradation. Bioch Biophys Acta 2010;1803:826-31.
19. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cellu Mol Life Sci 2011;68:3033-46.
20. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45.
21. Wickstrom SA, Lange A, Montanez E, Fassler R. The ILK/PINCH/parvin complex: the kinase is dead, long live the pseudokinase! EMBO J 2010;29:281-91.
22. Lossner D, Abou-Ajram C, Benge A, Aumercier M, Schmitt M, Reuning U. Integrin alphavbeta3 upregulates integrin-linked kinase expression in human ovarian cancer cells via enhancement of ILK gene transcription. J Cell Physiol 2009;220:367-75.
23. Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C, et al. Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res 2009;69:3308-16.
24. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:91-100.
25. Pecheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 2002;16:1266-68.
26. Cowden Dahl KD, Robertson SE, Weaver VM, Simon MC. Hypoxiainducible factor regulates alphavbeta3 integrin cell surface expression. Mol Biol Cell 2005;16:1901-12.
27. Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:9482-87.
28. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA 2001;98:1853-58.
29. Alain T, Morita M, Fonseca BD, Yanagiya A, Siddiqui N, Bhat M, et al. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res 2012;72:6468-76.
30. Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, et al. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 2007;67:7551-55.
31. Chung J, Bachelder RE, Lipscomb EA, Shaw LM, Mercurio AM. Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. J Cell Biol 2002;158: 165-74.
32. Lorger M, Krueger JS, O'Neal M, Staflin K, Felding-Habermann B. Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain. Proc Natl Acad Sci USA 2009;106: 10666-71.
33. Stupack DG, Cheresh DA. Integrins and angiogenesis. Curr Top Dev Biol 2004;64:207-38.